Science for a Healthier Tomorrow
Obesity medication combined with lifestyle counseling produced the greatest short-term weight reduction — but the evidence covers only about 6 to 12 months.
A network meta-analysis of 42 randomized trials in 3,835 children and adolescents aged 10 to 19 with obesity found that obesity medication combined with lifestyle counseling produced the greatest short-term (typically 6 to 12 months) BMI reduction, and that intensive lifestyle treatment alone also worked. The largest single estimate in the ranking — semaglutide plus counseling — rests on a limited number of studies, so it is a small-node network estimate rather than a settled size of effect.
What this means
In children and adolescents aged 10 to 19 with obesity, combining an obesity medication with lifestyle treatment produced the greatest short-term reduction in BMI across 42 randomized trials, and intensive lifestyle treatment alone also worked. The strongest single estimate, semaglutide plus counseling, came to a mean BMI difference of −8.31 kg/m² against control — but it is built on a limited number of studies, which makes it a small-node network estimate. Every outcome here covers only about 6 to 12 months; the analysis says nothing about long-term safety, growth, or what happens after treatment stops.
What the analysis compared
The paper is a systematic review and random-effects network meta-analysis of randomized controlled trials, reported to PRISMA standards. It pooled 42 trials with 3,835 children and adolescents aged 10 to 19 with obesity — median age 14.5 years (interquartile range 13.3 to 15.1) and 59.2% female — and searched Embase, CENTRAL, PsycINFO and PubMed from inception to 17 June 2025. A network meta-analysis compares several treatments at once by linking them through the comparisons each trial made, even when two treatments were never tested directly against each other. The trials covered lifestyle treatment alone (intensive health behavior and lifestyle treatment, or HBLT, and counseling), medications alone (GLP-1 receptor agonists, metformin, orlistat, and phentermine/topiramate), and medications added to lifestyle treatment, each against a control. Follow-up was short-term, typically 6 to 12 months.
What it found
The primary outcome was BMI. The largest reduction in the network came from semaglutide combined with counseling: a mean difference of −8.31 kg/m² (95% confidence interval −12.33 to −4.28) against control. In BMI z score — a measure of how far a child’s BMI sits from that of others of the same age and sex — the same combination produced a mean difference of −1.80 (95% CI −2.39 to −1.21). Intensive lifestyle treatment on its own also worked: a mean BMI difference of −3.85 kg/m² (95% CI −4.91 to −2.80), and a BMI z score difference of −0.89 (95% CI −1.17 to −0.61). More broadly, the authors report that every pharmacological treatment did more when paired with lifestyle treatment, with significantly greater BMI and BMI z score reductions than the same medications alone; the body-composition comparisons behind the secondary outcomes (waist circumference, fat mass, lean mass) were limited.
Why the largest number is the least certain
The semaglutide-plus-counseling figure tops the ranking, and it is also the estimate built on the fewest studies. In a network meta-analysis, an effect can rest on one trial or a thin set of trials connected to the rest of the network only indirectly, which makes it more sensitive to a single study’s quirks than an estimate pooled from many. A number that strong from a node that small is best read as the top of a ranking, not as a settled effect size.
The limits of the ranking
Three limits belong next to that result on every surface. First, everything measured is short-term — about 6 to 12 months. The analysis reports no data on durability after treatment stops, on growth, or on long-term safety. Second, a network ranking depends on how well-connected and consistent the network is, and direct head-to-head trials between drugs are sparse, so the ordering is only as strong as the indirect links beneath it. Third, the body-composition data (fat mass, lean mass) were limited, a point raised in a published comment on the paper. This is a comparative-effectiveness result — how treatments compare across trials, on average — not clinical guidance for any individual child, and not evidence that a medication is the right first step for a given patient. The paper is funded by Hong Kong Baptist University (initiation grant 160300 and Tier 1 Research Start-Up Grant 162894), with the funder playing no role in study design, conduct, data or the manuscript. One author reported consulting fees from Novo Nordisk, Eli Lilly and Rhythm Pharmaceuticals outside the submitted work, and another reported board roles with childhood-obesity scientific associations and related travel support; the remaining authors reported no other disclosures. The systematic review was registered with PROSPERO (CRD420251027387).
Where this sits
The American Academy of Pediatrics’ 2023 guideline (Hampl and colleagues) placed intensive lifestyle treatment as the foundation of pediatric obesity care and pharmacotherapy as an adjunct. This network analysis supports the lifestyle-foundation of that structure while arguing that, in combination, pharmacotherapy is a key component rather than solely an adjunct — and it adds the quantified ranking across drugs, lifestyle and combinations, the part that is new. The drug side is anchored by the 2022 adolescent semaglutide trial, and a newer medicine, tirzepatide, has been studied for obesity and diabetes prevention in adults but sits outside this pediatric network. What the ranking does not carry is length of evidence: the entire base is short-term, and that limit is the one the drug-marketing frame tends to leave out. Related Nutritious News coverage of a claims analysis found a nutrition-monitoring gap in young GLP-1 users Claims Study Finds a Nutrition Monitoring Gap in Young GLP-1 Users — a reminder that for young people on these drugs, the open questions run past weight change alone.
Terms explained
- Network meta-analysis: a method that compares three or more treatments at once by combining every direct comparison the trials made and inferring the missing ones indirectly. It can rank treatments that were never tested head-to-head, but those indirect links are only as reliable as the network’s connectedness.
- Mean difference (MD) and confidence interval (CI): the mean difference is the average gap between two groups on an outcome, in that outcome’s own units. The 95% confidence interval is the range that would contain the true value in 95 of 100 similar studies — here, for example, −8.31 kg/m² with a range of −12.33 to −4.28.
- BMI z score: a child’s BMI expressed relative to others of the same age and sex, so it tracks how far a measurement sits from the typical value for that group. A z score of 0 is average; negative values fall below it.
- Health behavior and lifestyle treatment (HBLT): structured programs combining diet, physical activity and behavior change, delivered at higher intensity than routine advice. HBLT is the lifestyle-only arm in this analysis.
- Short-term vs long-term outcomes: this analysis measured results at roughly 6 to 12 months. Long-term would mean following participants for years, including after treatment stops — to see whether weight loss holds, whether growth and development are affected, and what safety issues appear. None of that is in this dataset.
Sources
- Primary source: Wan K, Lei EF, Liu Y, Taddese AA, Ip P, Torbahn G, Weghuber D, Huang WY, Tam BT. “Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.” JAMA Pediatrics, published 2026-09-01. DOI: 10.1001/jamapediatrics.2026.2248 · PMID: 42329656. Peer-reviewed systematic review and random-effects network meta-analysis of randomized trials (PRISMA-reported). Full text accessed via the JAMA guest-access link; the paper’s funding and conflict-of-interest disclosures were read from the full text. PROSPERO registration: CRD420251027387.
- Landscape — the adolescent semaglutide trial: Weghuber D, et al. “Once-Weekly Semaglutide in Adolescents with Obesity.” N Engl J Med 2022;387(24):2245-2257. DOI: 10.1056/NEJMoa2208601 (abstract-level access; the randomized trial that anchors the largest effect estimate).
- Landscape — pediatric obesity guideline: Hampl SE, et al. “Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity.” Pediatrics 2023;151(2):e2022060640. DOI: 10.1542/peds.2022-060640 · PMID: 36622115 (abstract-level access; places intensive lifestyle treatment as foundational, pharmacotherapy as adjunct).
- Adjacent — newer pharmacology: Jastreboff AM, et al. “Tirzepatide for Obesity Treatment and Diabetes Prevention.” N Engl J Med 2025. DOI: 10.1056/NEJMoa2410819 (abstract-level access; adult study, outside this pediatric network).
